Breaking News Instant updates and real-time market news.

SYK

Stryker

$165.78

0.01 (0.01%)

, ZBH

Zimmer Biomet

$119.13

-0.75 (-0.63%)

10:23
02/27/18
02/27
10:23
02/27/18
10:23

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Stryker (SYK) upgraded to Neutral from Sell at Citi by analyst Amit Hazan, who believes supply issues at Zimmer Biomet (ZBH) could drive share gains for Stryker. 2. Chipotle (CMG) upgraded to Outperform from Neutral at Baird by analyst David Tarantino, who cited its new CEO and the potential for the company to demonstrate better sales/traffic momentum over the next 12-24 months. He believes it will support investor sentiment given the opportunity for the company to deliver strong earnings power if unit volumes begin to recover. 3. Itron (ITRI) upgraded to Buy from Hold at Cannacord Genuity by analyst Chip Moore, who said he has increased conviction in the company's forward earnings power and finds current share levels a "very compelling" entry point. He notes the stock is down 10% since the SilverSpring Networks deal announcement back in September. Moore's views the combination as compelling and has increased confidence in cost saving potential post close. 4. Winnebago (WGO) upgraded to Outperform from Market Perform at BMO Capital by analyst Gerrick Johnson, who said that the RV market growth -- currently in its 9th year -- will continue at a 10% pace, adding that the company's growth can outgain the competition because of its "operating improvement, enhanced product offering, and emerging trade-up cycle from first time buyers." The analyst also noted that Winnebago will benefit from lower corporate taxes while its stock trades at "significant" valuation discount. 5. Exelixis (EXEL) upgraded to Outperform from Perform at Oppenheimer by analyst Leah Rush Cann. The analyst is now applying a valuation methodology for profitable companies to Exelixis, since the company turned profitable for the full-year 2017. She expects Exelixis will continue to develop its commercial drugs, Cabometyx and Cometriq, while its partner Genentech (RHHBY) will continue to develop Cotellic. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

SYK

Stryker

$165.78

0.01 (0.01%)

ZBH

Zimmer Biomet

$119.13

-0.75 (-0.63%)

CMG

Chipotle

$328.01

16.1203 (5.17%)

ITRI

Itron

$70.40

0.85 (1.22%)

WGO

Winnebago

$45.20

1.05 (2.38%)

EXEL

Exelixis

$29.53

0.02 (0.07%)

RHHBY

Roche

$29.88

0.125 (0.42%)

  • 27

    Feb

  • 28

    Feb

  • 07

    Mar

  • 14

    Mar

  • 30

    May

SYK Stryker
$165.78

0.01 (0.01%)

01/29/18
RHCO
01/29/18
NO CHANGE
Target $179
RHCO
Buy
Stryker price target raised to $179 from $161 at SunTrust
SunTrust analyst Bruce Nudell raised his price target on Stryker to $179 after the company's preliminary Q4 earnings beat and FY17 outlook at the upper end of prior forecast. The analyst also cites favorable FX and higher Medsurg & Orthopedics forecasts while adding that he will watch the quarter results for hints on the overall health of the global hip/knee markets and continued uptake of the Mako robots. Nudell keeps his Buy rating on Stryker.
01/09/18
PIPR
01/09/18
NO CHANGE
Target $166
PIPR
Overweight
Stryker price target raised to $166 from $156 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raises his price target on Stryker to $166 after the company's preliminary Q4 earnings beat and FY17 outlook at the upper end of prior forecast. The analyst says the negative reaction in the stock price today due to management's commentary on anticipated tax headwind is a "great opportunity" to start building a position. O'Brien notes the stock is valued at a premium, but see "very few" medical technology names with a similar organic growth profile. The analyst keeps his Overweight rating on Stryker.
02/27/18
SBSH
02/27/18
UPGRADE
Target $166
SBSH
Neutral
Stryker upgraded to Neutral from Sell at Citi
Citi analyst Amit Hazan upgraded Stryker (SYK) to Neutral and raised his price target for the shares to $166 from $149. The analyst believes supply issues at Zimmer Biomet (ZBH) could drive share gains for Stryker.
02/01/18
OPCO
02/01/18
NO CHANGE
Target $165
OPCO
Perform
Stryker price target raised to $165 from $156 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Stryker to $165 from $156 following Q4 results. The analyst reiterates a Perform rating on the shares, citing valuation.
ZBH Zimmer Biomet
$119.13

-0.75 (-0.63%)

01/31/18
STFL
01/31/18
UPGRADE
Target $168
STFL
Buy
Stifel upgrades Zimmer Biomet to Buy on new CEO optimism
Stifel analyst Rick Wise upgraded Zimmer Biomet Holdings to Buy from Hold and raised his price target for the shares to $168 from $120. Under the new CEO, the analyst has greater conviction that the company can "gradually stabilize and, over time, re-accelerate growth." Wise cautious a turnaround will take time and that 2018-2020 estimates are likely to move lower. He believes, however, that this would represent a "clearing event," betting positioning Zimmer shares to outperform.
02/13/18
NEED
02/13/18
NO CHANGE
NEED
Needham a buyer of Medical Technologies product makers on Amazon headlines
After The Wall Street Journal report claiming that Amazon (AMZN) is attempting to become a major hospital supplier, Needham analyst Mike Matson said that he believes the e-commerce giant has typically disrupted middlemen much more than manufacturers. The analyst, who thinks Amazon's model may work for "lower tech" products but is unlikely to work with "higher tech" products, would be a buyer of Medical Technologies product maker stocks if they are down on weakness related to the headline risk represented by Amazon. However, Matson notes that he believe that Cantel Medical (CMD), CONMED (CNMD), Medtronic (MDT), Stryker (SYK) and Teleflex (TFX) generate a portion of their sales from "lower tech" products. Other stocks in MedTech manufacturing include AtriCure (ATRI), Cardiovascular Systems (CSII), Hill-Rom (HRC), K2M Group (KTWO), Mazor Robotics (MZOR), Zimmer Biomet (ZBH), Boston Scientific (BSX), Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI).
01/31/18
STFL
01/31/18
UPGRADE
STFL
Buy
Zimmer Biomet upgraded to Buy from Hold at Stifel
CMG Chipotle
$328.01

16.1203 (5.17%)

02/27/18
BARD
02/27/18
UPGRADE
BARD
Outperform
Chipotle upgraded to Outperform from Neutral at Baird
02/20/18
02/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Chipotle (CMG) upgraded to Hold from Sell at Stifel with analyst Chris O'Cull saying that his opinion of the company's fundamentals has not changed, but sentiment has improved and he believes investor optimism will likely outweigh fundamentals in the near-term. 2. Hyatt (H) and Marriott (MAR) were upgraded to In Line from Underperform at Evercore ISI. 3. Flowserve (FLS) upgraded to Sector Perform from Underperform at RBC Capital with analyst Deane Dray citing his expectations of an announcement of a turnaround plan from the new CEO and believes the stock may have bottomed, since the fourth quarter operating miss and "low-balled fiscal 2018 outlook" did not produce new selling pressure. 4. UPS (UPS) upgraded to Buy from Hold at Edward Jones. 5. Universal Display (OLED) upgraded to Buy from Hold at Needham with analyst James Ricchiuti saying he has been looking for the right entry point on the stock since the summer, and the recent 25% selloff from the high offers that opportunity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/20/18
FBCO
02/20/18
NO CHANGE
Target $290
FBCO
Neutral
Chipotle price target raised to $290 from $275 at Credit Suisse
Credit Suisse analyst Jason West raised his price target for Chipotle to $290 form $275 following the recent rally and as he believes the bar is still relatively low for future earnings power at the current stock price. The analyst reiterates a Neutral rating on the shares.
02/27/18
BARD
02/27/18
UPGRADE
Target $400
BARD
Outperform
Chipotle upgraded to Outperform with $400 price target at Baird
As previously reported, Baird analyst David Tarantino upgraded Chipotle to Outperform from Neutral. The analyst cited its new CEO and the potential for the company to demonstrate better sales/traffic momentum over the next 12-24 months. He believes it will support investor sentiment given the opportunity for the company to deliver strong earnings power if unit volumes begin to recover. Tarantino raised his price target to $400 from $315 on Chipotle shares.
ITRI Itron
$70.40

0.85 (1.22%)

01/02/18
RAJA
01/02/18
INITIATION
Target $84
RAJA
Strong Buy
Itron initiated with a Strong Buy at Raymond James
Raymond James analyst Pavel Molchanov initiated Itron with a Strong Buy rating and a price target of $84. The analyst says the company stands out as "the only U.S.-listed company substantially leveraged" to power grid efficiency improvement with smart grid technology as well as materializing Internet of Things deployment in lighting systems. Molchanov adds that Itron's "scarcity value and impressive free cash flow metrics must be balanced against the frequently lumpy quarterly results".
02/27/18
ADAM
02/27/18
UPGRADE
Target $84
ADAM
Buy
Canaccord upgrades Itron to Buy on 'very compelling' entry point
Canaccord Genuity analyst Chip Moore upgraded Itron to Buy from Hold and raised his price target for the shares to $84 from $78. The analyst has increased conviction in the company's forward earnings power and finds current share levels a "very compelling" entry point. He notes the stock is down 10% since the SilverSpring Networks deal announcement back in September. Moore's views the combination as compelling and has increased confidence in cost saving potential post close.
02/27/18
ADAM
02/27/18
UPGRADE
ADAM
Buy
Itron upgraded to Buy from Hold at Canaccord
01/03/18
01/03/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Itron (ITRI) initiated with a Strong Buy at Raymond James. 2. Extreme Networks (EXTR) initiated with an Outperform at JMP Securities. 3. Flex Pharma (FLKS) resumed with a Buy at Roth Capital. 4. Zynga (ZNGA) initiated with an Outperform at Consumer Edge. 5. Bank of the Ozarks (OZRK) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
WGO Winnebago
$45.20

1.05 (2.38%)

02/27/18
BMOC
02/27/18
UPGRADE
Target $60
BMOC
Outperform
Winnebago upgraded to Outperform at BMO Capital on continued RV market growth
As reported earlier, BMO Capital analyst Gerrick Johnson upgraded Winnebago to Outperform from Market Perform and raised his price target to $60 from $58. Johnson contends that the RV market growth - currently in its 9th year - will continue at a 10% pace, adding that the company's growth can outgain the competition because of its "operating improvement, enhanced product offering, and emerging trade-up cycle from first time buyers". The analyst also notes that Winnebago will benefit from lower corporate taxes while its stock trades at "significant" valuation discount.
02/27/18
BMOC
02/27/18
UPGRADE
BMOC
Outperform
Winnebago upgraded to Outperform from Market Perform at BMO Capital
01/26/18
NRCS
01/26/18
DOWNGRADE
NRCS
Neutral
Winnebago downgraded to Neutral on valuation at Northcoast
As previously reported, Northcoast downgraded Winnebago to Neutral from Buy. Analyst Seth Woolf said shares reflect company's opportunity to improve the business, but notes the towables business is nearing capacity, Grand Design RV growth will be driven by categories that may produce disappointing margin rates, and the Motorhome business is a "mess."
01/26/18
NRCS
01/26/18
DOWNGRADE
NRCS
Neutral
Winnebago downgraded to Neutral from Buy at Northcoast
EXEL Exelixis
$29.53

0.02 (0.07%)

02/27/18
OPCO
02/27/18
UPGRADE
Target $40
OPCO
Outperform
Exelixis upgraded to Outperform with $40 target at Oppenheimer
Oppenheimer analyst Leah Rush Cann upgraded Exelixis to Outperform from Perform with a $40 price target. The analyst is now applying a valuation methodology for profitable companies to Exelixis, since the company turned profitable for the full-year 2017. She expects Exelixis will continue to develop its commercial drugs, Cabometyx and Cometriq, while its partner Genentech will continue to develop Cotellic. Cann views the company's Q4 results as "strong."
02/27/18
OPCO
02/27/18
UPGRADE
OPCO
Outperform
Exelixis upgraded to Outperform from Perform at Oppenheimer
10/17/17
NEED
10/17/17
NO CHANGE
Target $33
NEED
Buy
Exelixis price target raised to $33 from $30 at Needham
Needham analyst Chad Messer raised his price target on Exelixis (EXEL) to $33, noting the latest trial data for advanced renal cell carcinoma treatment, Cabozantinib, positions it for near and long term growth. Messer says the results may be sufficient to allay competitive concerns from the recently approved Bayer (BAYRY) Stivarga, as cabozantinib offers a potentially more attractive efficacy profile.
01/04/18
PIPR
01/04/18
NO CHANGE
Target $37
PIPR
Overweight
Piper ups Exelixis target to $37, names a top pick for 2018
Piper Jaffray analyst Edward Tenthoff names Exelixis a top pick for 2018 and raised his price target for the shares to $37 from $33. The analyst expects Cabometyx growth from driven label expansion and is positive into the Phase III Cotexo data in the first half of 2018.
RHHBY Roche
$29.88

0.125 (0.42%)

01/15/18
SOCG
01/15/18
DOWNGRADE
SOCG
Sell
Roche downgraded to Sell from Hold at Societe Generale
Societe Generale analyst Justin Smith downgraded Roche to Sell and cut his price target for the shares to CHF 190 from CHF 250.The analyst sees downside risk to consensus estimates from generic competition and expects the stock to underperform.
02/12/18
LEER
02/12/18
NO CHANGE
Target $502
LEER
Outperform
Data from Regeneron Eylea competitors should lift some overhang, says Leerink
Leerink analyst Geoffrey Porges says that the "confusing and somewhat lackluster data" presented over the weekend for Eylea's theoretical competitors should lift some of the overhang that Regeneron's stock has suffered from over the last 6 months. Novartis' (NVS) brolucizumab pivotal trial is confusing, and the data incomplete, and the analyst has serious doubts about the drug's approvability. Secondly, the addition of Ang2 inhibition to VEGF inhibition, while theoretically intriguing, has so far been of modest benefit despite Roche's (RHHBY) posturing, he contends. Porges reiterates an Outperform rating and $502 price target on Regeneron's shares.
02/08/18
02/08/18
DOWNGRADE

Neutral
Regeneron downgraded to Neutral ahead of Roche readout at BTIG
As previously reported, BTIG analyst Dane Leone downgraded Regeneron (REGN) to Neutral from Buy, stating that he is optimistic that Roche's (RHHBY) coming read-out of the BOULEVARD study may show encouraging clinical results on Feb 13 to support a pivotal effort and may show VEGF + ANG2 inhibition may provide incremental benefits over VEGF therapy alone in DME and potentially wetAMD. He also noted that REGN1979 bi-specific has shown limited efficacy in patients with Agg-NHL.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $25
JEFF
Hold
Acorda remains takeover candidate after competitor data, says Jefferies
Jefferies analyst Michael Yee believes the positive Phase III topline results from Acorda Therapeutics (ACOR) competitor Sunovion for APL-130277 in Parkinson's patients came in as expected. While APL-130277 data compares favorably over Inbrija's 3.92 point difference at week 12, Yee cautions to compare directly head-to-head since patient baseline characteristics could be different. Acorda remains a "reasonably likely" acquisition candidate in 2018 given its $300M-$500M-plus Parkinson's asset Inbrija, Yee tells investors in a research note. The analyst does not think Biogen (BIIB) should buy the company, but sees other potential suitors in AbbVie (ABBV), Allergan (AGN), Mitsubishi, Roche (RHHBY) and Shire (SHPG). He believes a takeover price could be north of $2B. Yee keeps a Hold rating on Acorda with a $25 price target.

TODAY'S FREE FLY STORIES

03:10
07/19/18
07/19
03:10
07/19/18
03:10
General news
FX Action: USD-CAD has settled under 1.3200 »

FX Action: USD-CAD has…

02:35
07/19/18
07/19
02:35
07/19/18
02:35
General news
FX Update: The Dollar has mostly traded in narrow ranges »

FX Update: The Dollar…

01:45
07/19/18
07/19
01:45
07/19/18
01:45
General news
Asian Market Wrap »

Asian Market Wrap: Bond…

BHLB

Berkshire Hills Bancorp

$40.80

0.15 (0.37%)

22:34
07/18/18
07/18
22:34
07/18/18
22:34
Upgrade
Berkshire Hills Bancorp rating change at Compass Point »

Berkshire Hills Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

PG

Procter & Gamble

$79.71

-0.34 (-0.42%)

22:34
07/18/18
07/18
22:34
07/18/18
22:34
Downgrade
Procter & Gamble rating change at UBS »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

GWW

Grainger

$338.99

33.78 (11.07%)

22:33
07/18/18
07/18
22:33
07/18/18
22:33
Upgrade
Grainger rating change at UBS »

Grainger upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

MS

Morgan Stanley

$50.54

1.34 (2.72%)

22:32
07/18/18
07/18
22:32
07/18/18
22:32
Upgrade
Morgan Stanley rating change at Bernstein »

Morgan Stanley upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

ESTA

Establishment Labs

$0.00

(0.00%)

22:17
07/18/18
07/18
22:17
07/18/18
22:17
Syndicate
Establishment Labs 3.715M share IPO priced at $18.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

CNST

Constellation Pharmaceuticals

$0.00

(0.00%)

22:12
07/18/18
07/18
22:12
07/18/18
22:12
Syndicate
Constellation Pharmaceuticals 4M share IPO priced at $15.00 »

The deal size was reduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

CARB

Carbonite

$37.90

0.6 (1.61%)

22:09
07/18/18
07/18
22:09
07/18/18
22:09
Syndicate
Carbonite 5.463M share Secondary priced at $37.50 »

The company increased the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 02

    Aug

  • 16

    Aug

  • 19

    Jul

TLRY

Tilray

$0.00

(0.00%)

22:04
07/18/18
07/18
22:04
07/18/18
22:04
Syndicate
Tilray 9M share IPO priced at $17.00 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

JBLU

JetBlue

$19.97

0.44 (2.25%)

, EADSY

Airbus

$0.00

(0.00%)

20:47
07/18/18
07/18
20:47
07/18/18
20:47
Periodicals
JetBlue founder to launch new U.S. low-cost airline, LA Times says »

JetBlue (JBLU) founder…

JBLU

JetBlue

$19.97

0.44 (2.25%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

PTC

PTC

$98.51

-0.4 (-0.40%)

20:28
07/18/18
07/18
20:28
07/18/18
20:28
Recommendations
PTC analyst commentary at MUFG »

PTC price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

PM

Philip Morris

$82.16

-0.17 (-0.21%)

, UNP

Union Pacific

$141.26

2.96 (2.14%)

20:25
07/18/18
07/18
20:25
07/18/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PM

Philip Morris

$82.16

-0.17 (-0.21%)

UNP

Union Pacific

$141.26

2.96 (2.14%)

DHR

Danaher

$98.80

-0.78 (-0.78%)

BK

BNY Mellon

$55.64

1.59 (2.94%)

BX

Blackstone

$36.23

0.52 (1.46%)

BBT

BB&T

$52.99

1 (1.92%)

TRV

Travelers

$130.03

1.26 (0.98%)

PPG

PPG

$106.84

1.43 (1.36%)

KEY

KeyCorp

$20.30

0.24 (1.20%)

FITB

Fifth Third

$30.26

0.75 (2.54%)

NUE

Nucor

$65.65

1.045 (1.62%)

GPC

Genuine Parts

$94.64

0.47 (0.50%)

ADS

Alliance Data

$226.51

1.13 (0.50%)

DPZ

Domino's Pizza

$283.74

1.74 (0.62%)

DOV

Dover

$74.21

-0.37 (-0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 08

    Aug

  • 26

    Aug

  • 21

    Sep

  • 05

    Oct

  • 30

    Oct

FFKT

Farmers Capital Bank

$53.50

0.65 (1.23%)

20:23
07/18/18
07/18
20:23
07/18/18
20:23
Earnings
Farmers Capital Bank reports Q2 EPS 83c, consensus 73c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$71.49

0.06 (0.08%)

20:13
07/18/18
07/18
20:13
07/18/18
20:13
Recommendations
Anadarko analyst commentary at MUFG »

Anadarko price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

HES

Hess Corp.

$64.14

0.67 (1.06%)

20:00
07/18/18
07/18
20:00
07/18/18
20:00
Recommendations
Hess Corp. analyst commentary at MUFG »

Hess Corp price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

NBL

Noble Energy

$34.34

-0.11 (-0.32%)

19:52
07/18/18
07/18
19:52
07/18/18
19:52
Recommendations
Noble Energy analyst commentary at MUFG »

Noble Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

NDLS

Noodles & Company

$11.80

-0.35 (-2.88%)

, IBM

IBM

$144.44

0.98 (0.68%)

19:08
07/18/18
07/18
19:08
07/18/18
19:08
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

NDLS

Noodles & Company

$11.80

-0.35 (-2.88%)

IBM

IBM

$144.44

0.98 (0.68%)

BHLB

Berkshire Hills Bancorp

$40.80

0.15 (0.37%)

CL

Colgate-Palmolive

$64.81

-0.76 (-1.16%)

EGAN

eGain

$13.15

-0.75 (-5.40%)

EBAY

eBay

$37.95

0.13 (0.34%)

CCK

Crown Holdings

$45.12

-0.265 (-0.58%)

PTC

PTC

$98.51

-0.4 (-0.40%)

AXP

American Express

$102.98

1.84 (1.82%)

URI

United Rentals

$155.14

2.94 (1.93%)

AA

Alcoa

$47.90

-0.105 (-0.22%)

SPWH

Sportsman's Warehouse

$5.23

-0.16 (-2.97%)

RUN

Sunrun

$15.16

-0.02 (-0.13%)

CLX

Clorox

$129.50

-5.5 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 27

    Jul

  • 02

    Aug

  • 06

    Aug

  • 08

    Aug

  • 09

    Aug

  • 19

    Jul

GSBC

Great Southern Bancorp

$58.55

-0.2 (-0.34%)

19:03
07/18/18
07/18
19:03
07/18/18
19:03
Earnings
Great Southern Bancorp reports Q2 EPS 97c, consensus 94c »

Reports Q2 NII $41.2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMAB

OMA Airports

$45.82

-0.48 (-1.04%)

18:40
07/18/18
07/18
18:40
07/18/18
18:40
Hot Stocks
OMA Airports reports Q2 passenger traffic up 9.6% »

OMA generated a 25.7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OPTN

Optinose

$26.97

0.36 (1.35%)

18:35
07/18/18
07/18
18:35
07/18/18
18:35
Recommendations
Optinose analyst commentary at BMO Capital »

Optinose's Xhance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$31.73

-0.02 (-0.06%)

18:29
07/18/18
07/18
18:29
07/18/18
18:29
Periodicals
DOJ: AT&T-Time Warner ruling ignored 'basic economics,' FT reports »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 09

    Aug

SBGI

Sinclair Broadcast

$27.35

-0.65 (-2.32%)

, TRCO

Tribune Media

$34.09

0.79 (2.37%)

18:26
07/18/18
07/18
18:26
07/18/18
18:26
Hot Stocks
FCC votes unanimously to adopt hearing order on Sinclair-Tribune deal »

This evening, the Federal…

SBGI

Sinclair Broadcast

$27.35

-0.65 (-2.32%)

TRCO

Tribune Media

$34.09

0.79 (2.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 06

    Sep

RUN

Sunrun

$15.16

-0.02 (-0.13%)

, JKS

JinkoSolar

$13.70

-0.1 (-0.72%)

18:25
07/18/18
07/18
18:25
07/18/18
18:25
Downgrade
Sunrun, JinkoSolar, Canadian Solar, Vivint Solar rating change at Goldman Sachs »

Sunrun downgraded to…

RUN

Sunrun

$15.16

-0.02 (-0.13%)

JKS

JinkoSolar

$13.70

-0.1 (-0.72%)

CSIQ

Canadian Solar

$12.83

0.15 (1.18%)

VSLR

Vivint Solar

$5.20

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.